ANTIFIBROTIC THERAPY INCREASES RISK OF PULMONARY ARTERIAL HYPERTENSION IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

被引：0
|
作者：
Scullin, D. [1 ]
Barney, J. [1 ]
机构：
[1] Univ Alabama Birmingham, Internal Med, Birmingham, AL USA
来源：
CHEST | 2020年 / 157卷 / 06期
关键词：
Pulmonary fibrosis; pulmonary hypertension; Antifibrotics;
D O I：
10.1016/j.chest.2020.05.178
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：157A / 157A
页数：1
相关论文
共 50 条
  • [1] Antifibrotic therapy for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
    Teoh, A.
    Glenn, L.
    Corte, T.
    Holland, A.
    RESPIROLOGY, 2023, 28 : 202 - 202
  • [2] Effect of Antifibrotic Therapy on Survival in Patients With Idiopathic Pulmonary Fibrosis
    de Andrade, Joao A.
    Neely, Megan L.
    Hellkamp, Anne S.
    Culver, Daniel A.
    Kim, Hyun J.
    Liesching, Timothy
    Lobo, Leonard J.
    Ramaswamy, Murali
    Safdar, Zeenat
    Bender, Shaun
    Conoscenti, Craig S.
    Leonard, Thomas B.
    Palmer, Scott M.
    Snyder, Laurie D.
    CLINICAL THERAPEUTICS, 2023, 45 (04) : 306 - 315
  • [3] The impact of pulmonary arterial hypertension on idiopathic pulmonary fibrosis
    Fell, Charlene D.
    Martinez, Fernando J.
    CHEST, 2007, 131 (03) : 641 - 643
  • [4] Persistence of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis: A Pulmonary Fibrosis Foundation Patient Registry Study
    Kulkarni, Tejaswini
    Flaherty, Kevin
    Gupta, Sachin
    Tu, Yi-Hsuan
    Case, Amy Hajari
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2025, 22 (01) : 165 - 168
  • [5] The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis
    Kette, Stefano
    Reccardini, Nicolo
    Salton, Francesco
    Confalonieri, Paola
    Andrisano, Alessia
    Chianese, Maria
    De Nes, Anna
    Maggisano, Marta
    Galantino, Alessandra
    Nicolosi, Salvatore
    Mari, Marco
    Salotti, Andrea
    Angoni, Darina
    Chernovsky, Maria
    Hughes, Michael
    Confalonieri, Marco
    Mondini, Lucrezia
    Ruaro, Barbara
    PHARMACEUTICALS, 2025, 18 (03)
  • [6] Lung Cancer Incidence in Patients on Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
    Kadura, S.
    Barakat, A.
    Breeze, J.
    LaCamera, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [7] Prevalence and Characteristics of Patients Receiving Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
    Qiu, Ying
    Zhao, Ruizhi
    Elpers, Brandon
    Wang, Yuexi
    Xie, Lin
    Tang, Jackson
    Fischer, Aryeh
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [8] Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
    Toby M. Maher
    Mary E. Strek
    Respiratory Research, 20
  • [9] Pattern of Utilization for Antifibrotic Therapy in Idiopathic Pulmonary Fibrosis
    Sedarati, K.
    Gordon, J. A.
    Graham, W. B.
    Sridhar, S.
    Rawal, N.
    Mohajer, K.
    Knowles, N.
    Wei, K.
    Patino, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [10] Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
    Maher, Toby M.
    Strek, Mary E.
    RESPIRATORY RESEARCH, 2019, 20 (01)
12345